Xilio Therapeutics Says On Sept 10, It Got Deficiency Letter From Nasdaq That Co Was Not In Compliance With Minimum Bid Requirement
Portfolio Pulse from Benzinga Newsdesk
Xilio Therapeutics received a deficiency letter from Nasdaq on September 10, indicating non-compliance with the minimum bid price requirement.
September 13, 2024 | 8:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Xilio Therapeutics has been notified by Nasdaq for not complying with the minimum bid price requirement, which could lead to delisting if not rectified.
The deficiency letter from Nasdaq indicates that Xilio Therapeutics' stock price has fallen below the required minimum bid price. This could lead to negative investor sentiment and potential selling pressure, impacting the stock price negatively in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100